Zoetis (ZTS) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Zoetis (ZTS) right now is Leader in a structurally growing market: Zoetis is the largest company in animal health, a market supported by the long-run humanization of pets, growing pet ownership, and rising global protein demand for livestock. Revenue (2026 guidance) is ~$9.7 billion to $10.0 billion. If that keeps playing out, the setup is favourable; the risk to it is zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. No one can predict where ZTS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Zoetis (ZTS) higher?
1. Leader in a structurally growing market.
Zoetis is the largest company in animal health, a market supported by the long-run humanization of pets, growing pet ownership, and rising global protein demand for livestock. Owners increasingly treat pets as family and spend more on their care, giving Zoetis a durable, multi-year demand tailwind that is less tied to the economic cycle than many industries.
2. Innovation-driven franchises and pipeline.
Zoetis invests heavily in research and development and has built leading franchises in high-value categories, including dermatology (Apoquel, Cytopoint), parasiticides (the Simparica line), and monoclonal-antibody pain treatments such as Librela for dogs. A steady flow of new products and label expansions, backed by patents and vet relationships, helps sustain pricing power and growth.
3. Diversification and expanding adjacencies.
The business spans both companion animals and livestock, many species, and multiple product types (medicines, vaccines, diagnostics), which smooths results when any single category softens. Zoetis has also expanded into diagnostics and, through a planned acquisition of an animal-genomics business, aims to broaden its data and testing footprint alongside its therapeutics.
What could weigh on ZTS?
Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. As a premium-valued, high-quality name, the stock can carry an elevated multiple that leaves it vulnerable to de-rating if growth disappoints. It is a growth-oriented holding, not a deep-value or high-yield income stock.
How to think about a ZTS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ZTS guide and whether ZTS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ZTS outlook
The bottom line: what is driving Zoetis (ZTS) is Leader in a structurally growing market, with revenue (2026 guidance) at ~$9.7 billion to $10.0 billion. If that keeps playing out the setup is favourable; the risk is zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. No one can predict the price, so treat any ZTS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on ZTS
- ZTS stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is ZTS a buy? (the case for, the risks, and a framework to decide)
- Does ZTS pay a dividend?
Build a basket around ZTS with Walnut
Use Zoetis as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Zoetis (ZTS)?
+
No one can reliably predict where ZTS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Zoetis higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ZTS higher?
+
The main growth drivers are Leader in a structurally growing market; Innovation-driven franchises and pipeline; Diversification and expanding adjacencies. Whether they play out is the real question, not a guaranteed path.
What are the risks to ZTS?
+
Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. As a premium-valued, high-quality name, the stock can carry an elevated multiple that leaves it vulnerable to de-rating if growth disappoints. It is a growth-oriented holding, not a deep-value or high-yield income stock.
Will ZTS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Zoetis's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ZTS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ZTS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Why did Zoetis cut its 2026 guidance?
+
Zoetis trimmed its full-year 2026 outlook after softer results, pointing to fewer veterinary visits, increased price sensitivity among pet owners, and rising competition in key companion-animal categories. International and livestock growth partly offset weaker US companion-animal demand. The figures are approximate and can change each quarter; verify current guidance before relying on it.
Is animal health a growing market?
+
Yes. Spending on animal health has grown over the long run, supported by pet humanization, rising pet ownership, more advanced treatments, and global demand for animal protein from livestock. As the largest player, Zoetis is positioned to benefit from this trend, which is one of the main reasons investors treat it as a durable-growth holding.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.